BMC MAT Quick Start vs Columbia Psychiatry Pathways Usage & Stats

This app offers healthcare providers the latest evidence-based guidance for treating opioid and alcohol use disorders (OUD and AUD) assisting in the initiation of medications such as buprenorphine and naltrexone. This is an essential tool for those starting patients on these medications, providing step-by-step clinical decision trees and valuable resources for managing not only AUD and OUD but acute and chronic pain for patients already on buprenorphine or naltrexone. With interactive tools, treatment protocols, and patient messaging features, this app empowers clinicians to deliver life-saving care while improving while improving treatment outcomes for substance use disorders. More than 46 million people aged 12 or older (or 16.5% of the US population) met the DSM-5 criteria for having a substance use disorder (SUD) in the past year based on the latest data from the 2021 National Survey on Drug Use and Health (NSDUH). However, only about 6% of people received any treatment for their SUD. Providing addiction treatment, including the use of FDA- approved medications and behavioral health therapies, has been shown to save lives and increase retention in treatment. The interactive clinical algorithms in this app walk you through each step of the clinical decision- making process to help you care for patients with an OUD or AUD. The clinical algorithms are also available in PDF format for easy viewing along with ability to securely text message patient tools to get started on buprenorphine. Additionally, several other clinical tools and resources related to SUD are included. BMC MAT QUICK START FEATURES: CLINICAL ALGORITHMS * Buprenorphine Initiation Guide: Decision trees for starting patients with an opioid use disorder on buprenorphine who are not currently physically dependent on opioids, opioid-dependent and not yet in withdrawal, and opioid-dependent and in active withdrawal. * Initiation of Extended-Release Injectable Buprenorphine: Guidance for starting a patient on new weekly and monthly formation formulations of extended-release injectable buprenorphine. * Naltrexone Initiation for Alcohol Use Disorder: Guidance for starting a patient on naltrexone for the treatment of alcohol use disorder. * Naltrexone Initiation for Opioid Use Disorder: Guidance for starting a patient on naltrexone for the treatment of opioid use disorder. Includes strategies for managing opioid withdrawal during the required “washout period” prior to starting naltrexone and avoiding precipitated withdrawal. * Pain Management While on Buprenorphine for Opioid Use Disorder: Guidance for managing acute and chronic pain in patients already on buprenorphine for opioid use disorder. * Pain Management While on Naltrexone: Guidance for managing acute pain (both anticipated and unanticipated) and chronic pain in patients already on naltrexone for opioid use disorder. * New! List of medication classes to assist in the management of opioid withdrawal symptoms. CLINICAL TOOLS * DSM-5 criteria for diagnosis of an opioid use disorder * Clinical Opiate Withdrawal Scale (COWS) to measure the severity of opioid withdrawal * Alcohol Use Disorders Identification Test (AUDIT-C) to identify risky drinking patterns PATIENT HANDOUTS * Buprenorphine Initiation Guide: A guide to give to patients who are starting buprenorphine in the home or community setting. Note: This app is designed exclusively for the use of healthcare providers. This app is not intended for use to diagnose a disease or to cure, mitigate, treat, or prevent any condition or disease. It is the responsibility of the treating clinician to rely on their own experience and knowledge about their specific patient to determine dosages and the best treatment for that patient.
  • Apple App Store
  • Free
  • Medical

Store Rank

- -

Designed by expert psychiatrists from Columbia University and delivered via cutting-edge, interactive technology from avoMD, this evidence-based app provides a practical and easy-to-use treatment algorithm for major depression. This app incorporates Columbia’s Accelerated Sequential Antidepressant Protocol (ASAP) © 2021 The Trustees of Columbia University in the City of New York. Complete with calculators to assess depression severity (PHQ-9 and Columbia Depression Scale), bipolar screening, and suicide risk assessment, this app puts all the information you need to treat depression at your fingertips. Also included are clinical pearls such as how to titrate antidepressants and manage common side effects. A revamp of the STAR*D Trial published in 2006, ASAP recommends rapid titrations and follow-up with a focus on the 7 best-tolerated generic antidepressants, providing a quicker and easier way to treat depression. Columbia Psychiatry Pathways is intended for use in outpatient settings by psychiatrists, primary care physicians, nurse practitioners, physician assistants, medical students, residents, and trainees as they treat patients with depression. FEATURES: - Designed by experts from Columbia University's Department of Psychiatry and delivered via avoMD's next-gen decision support technology - Regularly updated to reflect the latest research, with external links to the evidence - Provides clinical pearls for depression treatment, including a walkthrough of titration recommendations, management of common side effects, and more - Covers the 7 essential meds you need to know to effectively treat outpatient depression - Includes recommendations on managing DSM-5 depression and screening for bipolar disorder and suicide risk - Measure symptom severity using built-in calculators for Patient Health Questionnaire-9 item (PHQ-9) and the Columbia Depression Scale - Intended for outpatient settings to aid psychiatrists, primary care physicians, nurse practitioners, physician assistants, and trainees make real-time psychopharmacologic decisions - Functions as a teaching and learning tool for program directors, residents, med students, and other trainees Ranked #3 in NIH funding and in the top 5 psychiatry hospitals in the country by US News, the Department of Psychiatry at Columbia University has been a preeminent academic psychiatry department for over 100 years. Columbia Psychiatry faculty have led the development of the Diagnostic and Statistical Manual of Mental Disorders (DSM) and served as leaders in the field including the current National Institutes of Mental Health Director. The inventors of this clinical algorithm are J. John Mann, MD, co-director of Columbia’s Center for the Prevention and Treatment of depression and a leading researcher in the field of mood disorders, and Ravi N. Shah, MD, MBA, a pioneer in digital mental health and the department’s Chief Innovation Officer. avoMD transforms clinical guidelines, pathways, and algorithms into interactive, next-gen decision support apps, made available as standalone mobile and web apps and via EHR integrations. Leading academic medical centers, urgent cares, and trainee programs are using avoMD to digitize their clinical content and put them in the hands of their providers or distribute them externally. In randomized control trials and usability studies, the software has been shown to save providers time while improving clinical accuracy. Current investors and supporters include Columbia University’s Lang Entrepreneurship Center, Mount Sinai Innovation Partners’ Elementa Labs, StartUp Health, and 500 Startups. The team is led by physicians and informaticians from Columbia, Harvard, and Yale. Subscriptions ($19.99 / year) automatically renew unless auto-renew is turned off. Cancellations at least 24 hours prior to subscription renewal will not be charged. You can manage your subscription and auto-renewal from your Apple ID account settings after purchase.
  • Apple App Store
  • Free
  • Medical

Store Rank

- -

BMC MAT Quick Start vs. Columbia Psychiatry Pathways ranking comparison

Compare BMC MAT Quick Start ranking trend in the past 28 days vs. Columbia Psychiatry Pathways

Rank

No Data Available

BMC MAT Quick Start vs. Columbia Psychiatry Pathways ranking by country comparison

Compare BMC MAT Quick Start ranking trend in the past 28 days vs. Columbia Psychiatry Pathways

No Data to Display

Compare to any site with our free trial

Get started
BMC MAT Quick Start VS.
Columbia Psychiatry Pathways

December 26, 2024